ZEINCRO, a specialist provider of clinical research services in Greece, Turkey and Cyprus, today announced it is consolidating with Trial Masters Ltd, a contract research organization managing clinical trials in Hungary and Romania.
Athens, Greece and Budapest, Hungary – June 11, 2012 – ZEINCRO, a specialist provider of clinical research services in Greece, Turkey and Cyprus, today announced it is consolidating with Trial Masters Ltd, a contract research organization managing clinical trials in Hungary and Romania.
With a team of more than 140 people and over a decade’s experience, the expanded ZEINCRO Group, will be ideally positioned to offer to its global drug development customers clinical trial services in a broader geographical region in Central- and South- Eastern Europe (CSEE).
“Adding Trial Masters to ZEINCRO Group will extend our geographic reach and allow us to work on larger-scale projects,” commented Prof. Gregory Sivolapenko, Chairman of ZEINCRO Group. “Both our teams have forged strong links with local authorities and the healthcare community, giving us a unique and in-depth understanding of the regions in which we operate and enabling us to deliver bespoke clinical research services that are flexible and ethical, maximizing patient recruitment and compliance.”
Supplementary to clinical research services in CSEE, ZEINCRO Group provides specialized services in risk management plans, pharmacovigilance, post-marketing safety and efficacy studies as well as regulatory affairs.
Trial Masters CEO, Dr János Demeter, added: “We are excited to be joining ZEINCRO Group. This is a natural fit as we both share the same core values and fundamental approach to successfully delivering clinical development programs. As we continue our local presence but also become part of a larger organization, we will be able to enhance the support we offer to our customers.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.